6 terminated. 6 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Terminated 6 |
| Phase 3 | 3 | Terminated 3 |
| Phase 1 | 1 | Terminated 1 |
Follow Myelitis: new trials by email Literature Review of Myelitis trials Research Report on Myelitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder Eculizumab - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 2 / Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 5 | 2020-01-14 | 2024-09-25 |
| IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV), Reference IPV, sIPV Placebo - Poliomyelitis | Phase 1 / Phase 2 | Terminated | Takeda | 340 | 2017-06-07 | 2020-01-31 |
| Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome Flebogamma® 5% DIF, Placebo - Post-polio Syndrome | Phase 2 / Phase 3 | Terminated | Instituto Grifols, S.A. | 191 | 2014-09-23 | 2025-12-05 |
| Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Tamibarotene - HTLV-I-Associated Myelopathy | Phase 2 / Phase 3 | Terminated | St. Marianna University School of Medicine | 15 | 2011-01-01 | 2026-10-08 |
| Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age. GSK2202083A vaccine, Infanrix hexa, Menjugate - Tetanus, Poliomyelitis | Phase 2 | Terminated | GlaxoSmithKline | 16 | 2009-04-01 | 2018-06-06 |
| The HAM Infliximab Study Infliximab - HTLV-I-associated Myelopathy | Phase 2 | Terminated | Imperial College London | 3 | 2008-10-01 | 2013-04-15 |
Paraparesis, Tropical Spastic (2) · Poliomyelitis (2) · Demyelinating Diseases (1) · Diphtheria (1) · Haemophilus Infections (1) · Hepatitis B (1) · Myelitis, Transverse (1) · Neuromyelitis Optica (1) · Optic Neuritis (1) · Postpoliomyelitis Syndrome (1) · Recurrence (1) · Tetanus (1)
Central Nervous System Diseases (6) · Central Nervous System Infections (6) · Infections (6) · Nervous System Diseases (6) · Neuroinflammatory Diseases (6) · Spinal Cord Diseases (6) · RNA Virus Infections (5) · Virus Diseases (5) · Enterovirus Infections (3) · Neuromuscular Diseases (3) · Picornaviridae Infections (3) · Deltaretrovirus Infections (2) · HTLV-I Infections (2) · Neurodegenerative Diseases (2)
Immunoglobulins, Intravenous (1) · Infliximab (1) · diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (1) · eculizumab (1) · gamma-Globulins (1) · tamibarotene (1)
Alexion Pharmaceuticals, Inc. (1) · GlaxoSmithKline (1) · Imperial College London (1) · Instituto Grifols, S.A. (1) · St. Marianna University School of Medicine (1) · Takeda (1)
Canada (2) · Germany (2) · Italy (2) · Japan (2) · Spain (2) · United States (2) · Czechia (1) · Denmark (1) · Netherlands (1) · Panama (1) · Poland (1) · Slovakia (1) · South Korea (1) · United Kingdom (1)
Graham P Taylor, MD (1) · Marinos Dalakas, MD (1) · Yoshihisa Yamano, MD (1)
2019 (1)